Surmodics, Inc. (NASDAQ:SRDX) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Surmodics, Inc. has received a consensus recommendation of "Hold" from analysts, with one analyst urging a sell, three recommending a hold, and one suggesting a buy.
• The average one-year price target for Surmodics shares is set at $43.00 according to recent analyst reports.
• Institutional investors hold a significant majority of Surmodics' stock, owning 96.63%, with several increasing their positions in the company recently.

Surmodics, Inc. (NASDAQ:SRDX - Get Free Report) has received a consensus recommendation of "Hold" from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $43.00.

Several equities analysts recently weighed in on SRDX shares. Zacks Research upgraded Surmodics to a "hold" rating in a research report on Tuesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Surmodics in a research report on Saturday, September 27th. Finally, Barrington Research reissued a "market perform" rating on shares of Surmodics in a research report on Monday, August 11th.

Institutional Investors Weigh In On Surmodics

A number of institutional investors have recently added to or reduced their stakes in SRDX. Russell Investments Group Ltd. raised its position in Surmodics by 705.9% in the second quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company's stock valued at $37,000 after purchasing an additional 1,080 shares during the period. BNP Paribas Financial Markets raised its position in Surmodics by 67.6% in the second quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company's stock valued at $43,000 after purchasing an additional 579 shares during the period. Tower Research Capital LLC TRC raised its position in Surmodics by 289.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,730 shares of the company's stock valued at $51,000 after purchasing an additional 1,286 shares during the period. Strs Ohio purchased a new position in Surmodics in the first quarter valued at about $122,000. Finally, AlphaQuest LLC purchased a new position in Surmodics in the first quarter valued at about $232,000. Hedge funds and other institutional investors own 96.63% of the company's stock.

Surmodics Price Performance

Shares of Surmodics stock traded down $0.78 on Friday, hitting $29.12. The company's stock had a trading volume of 92,862 shares, compared to its average volume of 187,766. Surmodics has a 52-week low of $26.00 and a 52-week high of $40.38. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The firm has a fifty day moving average price of $34.14 and a 200-day moving average price of $30.97. The company has a market capitalization of $416.42 million, a P/E ratio of -23.67 and a beta of 1.31.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.27. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. The business had revenue of $29.57 million for the quarter, compared to analyst estimates of $28.04 million. Surmodics has set its FY 2025 guidance at -0.350--0.200 EPS. On average, equities research analysts expect that Surmodics will post 0.2 earnings per share for the current fiscal year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.